Careers  |  Sign In  |  Register  |   Twitter

Latest in Allergy & Clinical Immunology

TXA-709 is a new type of antibiotic being developed by TAXIS Pharmaceuticals. The antibiotic specifically targets variants of the MRSA bacteria. TXA-709, a FtsZ-targeting benzamide prodrug, should be able to circumvent the problem of antibiotic resistance in certain bacterial infections by targeting...
The unique pharmacokinetic properties of TXA-709 may allow it to effectively treat staphylococcus aureus infections, including MRSA, while reducing the possibility of patients developing a resistance to the antibiotic. Animal model studies have shown that TXA-709, a drug being developed by TAXIS...
Phase III Trial of VSV-EBOV vaccine in Conakry, Guinea yields 100% effective results for individual immunity against the Ebola virus.